SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials

An immunotherapy trial often uses the phase I/II design to identify the optimal biological dose, which monitors the efficacy and toxicity outcomes simultaneously in a single trial. The progression‐free survival rate is often used as the efficacy outcome in phase I/II immunotherapy trials. As a resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yifei, Guo, Beibei, Cao, Sha, Zhang, Chi, Zang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Main Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481656/
https://www.ncbi.nlm.nih.gov/pubmed/35332674
http://dx.doi.org/10.1002/pst.2209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481656/
https://www.ncbi.nlm.nih.gov/pubmed/35332674
http://dx.doi.org/10.1002/pst.2209

Ejemplares similares